Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||prostate cancer||no benefit||VT-464||Phase II||Actionable||In a Phase II trial, Seviteronel (VT-464) monotherapy demonstrated an undesirable toxicity profile and limited activity, with only 6% (1/17) of patients with metastatic castration-resistant prostate cancer achieved significant PSA response (PMID: 32327394).||32327394|